It’s a sobering statistic: 1 in 8 women in the United States will be diagnosed with breast cancer during her lifetime.1

Morgan Pressel's 18th annual Morgan & Friends event raised a record $1,022,000 to support the fight against breast cancer. Pressel, 36, lost her mother Kathy to breast cancer in 2003, and her memory is at the heart of the mission.

The U.S. Food and Drug Administration has approved AstraZeneca and partner Daiichi Sankyo's precision drug to treat a type of breast cancer, the health regulator said on Friday.

Danielle Fishel is sharing an update about her health, saying she has completed “active cancer treatment” following her announcement in August that she was diagnosed with DCIS, which stands for ductal carcinoma in situ and is a form of breast cancer.

Virginia G. Kaklamani, MD, DSc, discusses findings from the phase 3 TROPION-Breast01 trial of datopotamab deruxtecan.

Technology could soon do more than assist doctors. Thanks to advancements in cancer-identifying AI, it could actively save lives. A new study recently showcased how AI can revolutionize breast cancer detection, improving accuracy and easing radiologists’ workload.

As cancer treatment costs have increased, identifying and treating early-stage cancer sooner reduces expenses and improves patient outcomes.

The American Cancer Society has released its latest report on cancer in the United States, revealing both encouraging and concerning trends.

As supported by data from the phase 3 TROPION-Breast01 trial, datopotamab deruxtecan is now an FDA-approved treatment for patients with HR-positive, HER2-negative breast cancer.

Datroway has been approved for unresectable or metastatic HR+, HER2- breast cancer after endocrine therapy and chemotherapy.

Breast cancer detection in its early stages significantly improves survival rates, according to medical experts. While regular screenings remain crucial,